MINNEAPOLIS, Aug. 27, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences:
2025 Wells Fargo Healthcare Conference
September 3, 2025
10:15 AM EDT
Baird 2025 Global Healthcare Conference
September 9, 2025
9:05 AM EDT
Morgan Stanley 23rd Annual Global Healthcare Conference
September 10, 2025
10:45 AM EDT
A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: LinkedIn, X or YouTube.
Contact: David Clair, Vice President, Investor Relations & Corporate Development
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$62.71 |
| Daily Change: | 0.84 1.36 |
| Daily Volume: | 589,156 |
| Market Cap: | US$9.760B |
October 15, 2025 October 09, 2025 September 26, 2025 August 06, 2025 August 05, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
